Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2010 |
| End Date: | January 2016 |
The purpose of the study is to determine if participants who receive the GVHD prophylaxis
medication pentostatin will have less severe hepatic toxicities than those receiving MTX.The
study is estimated to have sufficient statistical power to ascertain at least a 20%
improvement in day 42 NCI CTC grade 2 or above hepatic toxicity-free survival in pentostatin
recipients.
Participants will be randomized to receive either methotrexate (MTX) or pentostatin for
graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow
transplant from an HLA-matched related or unrelated donor. All participants will receive a
standard backbone GVHD regimen (tacrolimus and sirolimus) and conditioning
(cyclophosphamide/TBI). A risk-adapted approach will be used during conditioning to further
minimize the risk of leukemia relapse based on two factors:
1. Lymphoid versus myeloid primary disease.
2. KIR compatibility between donor and host.
We found this trial at
1
site
Click here to add this to my saved trials
